Key Challenges in Developing Products from Transgenic Plants

  • Gauri Nerkar
  • G. S. Suresha
  • Bakshi Ram
  • C. Appunu


The use of plants for the production of plant-made pharmaceuticals (PMPs), plant-made vaccines (PMVs) and plant-made substances of industrial interests through transgenic approach is the sole objective of plant molecular (PM) farming, and it holds great promises in the plant industry. PM farming is advantageous in terms of saving production costs, large-scale production of drugs, animal and human virus-free products, easier storage and transportation of drugs and oral applicability (e.g. edible vaccines). Plant system also offers different platforms, viz. seed-, leaf-, stem-, root- and whole plant-based production in transgenic lines. The other systems such as bacterial, microbial eukaryotes, mammalian cells, insect cells and transgenic animals are expensive. Therefore, transgenic plants have been the subject of considerable attention as new generation bioreactors with respect to their advantages, such as the safety of recombinant proteins (antibodies, enzymes, vaccines, growth factors, etc.) and their potential for the large-scale and low-cost production. However, some of the key challenges that PM farming is facing include technical, economic, safety and regulatory as well as public acceptance. This chapter discusses in detail the challenges in obtaining products from transgenic plants such as expression of the recombinant proteins, downstream processing and purification, glycosylation, regulatory challenges and environmental risks.


Plant-made pharmaceuticals Plant molecular farming Vaccines Enzymes Recombinant proteins Glycosylation 


  1. Ahmad K (2014) Molecular farming: Strategies, expression systems and bio-safety considerations. Plant Breed 50:1–10Google Scholar
  2. Alireza T, Nader RE (2015) Molecular farming in plants. In: El-Shemy H (ed) Plants for the future. Intech Open. Google Scholar
  3. Apel W, Schulze WX, Bock R (2010) Identification of protein stability determinants in chloroplasts. Plant J 63:636–650PubMedPubMedCentralCrossRefGoogle Scholar
  4. Appunu C, Ram B, Subramonian N (2017) Sugarcane: an efficient platform for molecular farming. In: Mohan (ed) Sugarcane biotechnology: challenges and prospects. Springer Nature, Cham, pp 87–110CrossRefGoogle Scholar
  5. Arakawa T, Tsumoto K, Ejima D (2014) Alternative downstream processes for production of antibodies and antibody fragments. Biochim Biophys Acta 1844:2032–2040PubMedCrossRefPubMedCentralGoogle Scholar
  6. Aviezer D, Brill-Almon E, Shaaltiel Y et al (2009) A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS One 4:e4792PubMedPubMedCentralCrossRefGoogle Scholar
  7. Bock R (2007) Plastid biotechnology: prospects for herbicide and insect resistance, metabolic engineering and molecular farming. Curr Opin Biotechnol 18:100–106PubMedCrossRefPubMedCentralGoogle Scholar
  8. Bock R (2014) Engineering chloroplasts for high-level foreign protein expression. In: Maliga P (ed) Chloroplast biotechnology: methods and protocols, methods in molecular biology, vol. 1132., © Springer Science & Business Media, New YorkGoogle Scholar
  9. Bohmert-Tatarev K, McAvoy S, Daughtry S, Peoples OP, Snell KD (2011) High levels of bioplastic are produced in fertile transplastomic tobacco plants engineered with a synthetic operon for the production of polyhydroxybutyrate. Plant Physiol 155:1690–1708PubMedPubMedCentralCrossRefGoogle Scholar
  10. Bundó M, Montesinos L, Izquierdo E, Campo S, Mieulet D, Guiderdoni E et al (2014) Production of cecropin A antimicrobial peptide in rice seed endosperm. BMC Plant Biol 14:102PubMedPubMedCentralCrossRefGoogle Scholar
  11. Butelli E, Titta L, Giorgio M, Mock HP, Matros A, Peterek S et al (2008) Enrichment of tomato fruit with health-promoting anthocyanin by expression of select transcription factors. Nat Biotechnol 26:1301–1308PubMedCrossRefPubMedCentralGoogle Scholar
  12. Buyel JF, Fischer R (2014a) Downstream processing of biopharmaceutical proteins produced in plants: the pros and cons of flocculants. Bioengineered 5:138–142PubMedPubMedCentralCrossRefGoogle Scholar
  13. Buyel JF, Fischer R (2014b) Flocculation increases the efficacy of depth filtration during the downstream processing of recombinant pharmaceutical proteins produced in tobacco. Plant Biotechnol J 12:240–252PubMedCrossRefPubMedCentralGoogle Scholar
  14. Buyel JF, Fischer R (2014c) Characterization of complex systems using the design of experiments approach: transient protein expression in tobacco as a case study. J Vis Exp 83:e51216Google Scholar
  15. Buyel JF, Fischer R (2014d) Scale-down models to optimize a filter train for the downstream purification of recombinant pharmaceutical proteins produced in tobacco leaves. Biotechnol J 9:415–425PubMedCrossRefPubMedCentralGoogle Scholar
  16. Buyel JF, Fischer R (2014e) Generic chromatography-based purification strategies accelerate the development of downstream processes for biopharmaceutical proteins produced in plants. Biotechnol J 9:566–577PubMedCrossRefPubMedCentralGoogle Scholar
  17. Buyel JF, Gruchow HM, Boes A, Fischer R (2014) Rational design of a host cell protein heat precipitation step can simplify the subsequent purification of recombinant proteins fromtobacco. Biochem Engg J 88:162–170CrossRefGoogle Scholar
  18. Buyel JF, Opdensteinen P, Fischer R (2015) Cellulose-based filter aids increase the capacity of depth filters during the downstream processing of plant-derived biopharmaceutical proteins. Biotechnol J 10:584–591PubMedCrossRefPubMedCentralGoogle Scholar
  19. Chan HT, Daniell H (2015) Plant-made oral vaccines against human infectious diseases-Are we there yet? Plant Biotechnol J 13:1056–1070PubMedPubMedCentralCrossRefGoogle Scholar
  20. Chan HT, Chia MY, Pang VF, Jeng CR, Do YY, Huang PL (2013) Oral immunogenicity of porcine reproductive and respiratory syndrome virus antigen expressed in transgenic banana. Plant Biotechnol J 11:315–324PubMedCrossRefPubMedCentralGoogle Scholar
  21. Chandra S, Chandra R (2011) Engineering secondary metabolite production in hairy roots. Phytochem Rev 10:371–395CrossRefGoogle Scholar
  22. Commandeur U, Twyman R, Fischer R (2003) The biosafety of molecular farming in plants. AgBiotechNet:5Google Scholar
  23. Corrado G, Karali M (2009) Inducible gene expression systems and plant biotechnology. Biotechnol Adv 27:733–743PubMedCrossRefPubMedCentralGoogle Scholar
  24. Dai Z, Hooker B, Anderson D, Thomas S (2000) Expression of Acidothermus cellulolyticus endoglucanase E1 in transgenic tobacco: biochemical characteristics and physiological effects. Transgenic Res 9:43–54PubMedCrossRefPubMedCentralGoogle Scholar
  25. Daniell H, Singh ND, Mason H, Streatfield SJ (2009) Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 14:669–679PubMedPubMedCentralCrossRefGoogle Scholar
  26. EMEA Committee for Proprietary Medicinal Products (CPMP) (2002) Points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants. EMA, London (EMEA/CPMP/BWP/764/02)Google Scholar
  27. EMEA Committee for Proprietary Medicinal Products (CPMP) (2008) Guideline on the Quality of Biological Active Substances Produced by Stable Transgene Expression in Higher Plants. London, UK: EMA (EMEA/CHMP/BWP/48316/2006)Google Scholar
  28. FDA/USDA (2002) Draft guidance. Drugs, biologics and medical devices derived from bioengineered plants for use in humans and animals. FDA, RockvilleGoogle Scholar
  29. Fichtner F, UrreaCastellanos R, Ülker B (2014) Precision genetic modifications: a new era in molecular biology and crop improvement. Planta 239:921–939. CrossRefPubMedPubMedCentralGoogle Scholar
  30. Fischer R, Emans NJ, Twyman RM, Schillberg S (2004) Molecular farming in plants: technology platforms. Encyclopedia Plant Crop Sci:753–756.
  31. Fischer R, Schillberg S, Hellwig S, Twyman RM, Drossard J (2012) GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Adv 30:434–439PubMedCrossRefPubMedCentralGoogle Scholar
  32. Fischer R, Schillberg S, Buyel JF, Twyman RM (2013) Commercial aspects of pharmaceutical protein production in plants. Curr Pharm Des 19:5471–5477PubMedCrossRefPubMedCentralGoogle Scholar
  33. Fischer R, Vasilev N, Twyman RM, Schillberg S (2015) High-value products from plants: the challenges of process optimization. Curr Opin Biotechnol 32:156–162PubMedCrossRefGoogle Scholar
  34. Folayan MO, Yakubu A, Haire B, Peterson K (2016) Ebola vaccine development plan: ethics, concerns and proposed measures. BMC Med Ethics 17:10. CrossRefPubMedPubMedCentralGoogle Scholar
  35. Gottschalk U (2007) Large scale manufacturing of monoclonal antibodies: technology update and future trends.. Presentation in the course of conference on Plant-based Vaccines and Antibodies, PBVA 2007, from 18th to 20th June in Verona, ItalyGoogle Scholar
  36. Gottschalk U (2008) Bio separation in antibody manufacturing: the good, the bad and the ugly. Biotechnol Prog 24:496–503PubMedCrossRefGoogle Scholar
  37. He ZM, Jiang XL, Qi Y, Luo DQ (2008) Assessment of the utility of the tomato fruit-specificE7 promoter for driving vaccine antigen expression. Genetica 133:207–214PubMedCrossRefGoogle Scholar
  38. Hennig A, Bonfig K, Roitsch T, Warzecha H (2007) Expression of the recombinant bacterial outer surface protein A in tobacco chloroplasts leads to thylakoid localization and loss of photosynthesis. FEBS J 274:5749–5758PubMedCrossRefGoogle Scholar
  39. Hensel G, Floss DM, Arcalis E, Sack M, Melnik S, Altmann F et al (2015) Transgenic production of an anti HIV antibody in the barley endosperm. PLoS One 10:e0140476PubMedPubMedCentralCrossRefGoogle Scholar
  40. Herz S, Fubl M, Steiger S, Koop H-U (2005) Development of novel types of plastid transformation vectors and evaluation of factors controlling expression. Transgenic Res 14:969–982PubMedCrossRefPubMedCentralGoogle Scholar
  41. Holland T, Blessing D, Hellwig S, Sack M (2013) The in-line measurement of plant cell biomass using radio frequency impedance spectroscopy as a component of process analytical technology. Biotechnol J 8:1231–1240PubMedPubMedCentralGoogle Scholar
  42. Hudson LC, Garg R, Bost KL, Piller KJ (2014) Soybean seeds: a practical host for the production of functional subunit vaccines. Biomed Res Int 2014:13CrossRefGoogle Scholar
  43. Jaeger G, Scheffer S, Jacobs A et al (2002) Boosting heterologous protein production in transgenic dicotyledonous seeds using Phaseolus vulgaris regulatory sequences. Nat Biotechnol 20:1265–1268PubMedCrossRefPubMedCentralGoogle Scholar
  44. Jouzani GS, Tohidfar M (2013) Plant molecular farming: future prospects and biosafety challenges. Biosafety 2:e136CrossRefGoogle Scholar
  45. Juárez P, Presa S, Espí J, Pineda B, Antón MT, Moreno V et al (2012) Neutralizing antibodies against rotavirus produced in transgenically labelled purple tomatoes. Plant Biotechnol J 10:341–352PubMedCrossRefPubMedCentralGoogle Scholar
  46. Kim NS, Kim TG, Kim OH, Ko EM, Jang YS, Jung ES et al (2008a) Improvement o f recombinant hGM-CSF production by suppression of cysteine proteinase gene expression using RNA interference in a transgenic rice culture. Plant Mol Biol 68:263–275PubMedCrossRefPubMedCentralGoogle Scholar
  47. Kim TG, Baek MY, Lee EK, Kwon TH, Yang MS (2008b) Expression of human growth hormonein transgenic rice cell suspension culture. Plant Cell Rep 27:885–891PubMedCrossRefPubMedCentralGoogle Scholar
  48. Krupp LB et al (2003) Study and treatment of post Lyme disease (STOP-LD) a randomized double masked clinical trial. Neurology 60:1923–1930PubMedCrossRefPubMedCentralGoogle Scholar
  49. Kusnadi AR, Nikolov ZL, Howard JA (1997) Production of recombinant proteins in transgenic plants: Practical considerations. Biotechnol Bioeng 56:473–484PubMedCrossRefPubMedCentralGoogle Scholar
  50. Lamphear BJ, Jilka JM, Kesl L, Welter M, Howard JA, Streatfield SJ (2004) A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine 22:2420–2424PubMedCrossRefPubMedCentralGoogle Scholar
  51. Li J, Stoddard TJ, Demorest ZL, Lavoie P-O, Luo S, Clasen BM et al (2016) Multiplexed,targeted gene-editing in Nicotiana benthamiana for glyco-engineering and monoclonal antibody production. Plant Biotechnol J 14:533–542PubMedCrossRefPubMedCentralGoogle Scholar
  52. Lienard D, Sourrouille C, Gomord V, Faye L (2007) Pharming and transgenic plants. Biotechnol Annu Rev 13:115–147PubMedCrossRefPubMedCentralGoogle Scholar
  53. Ma JKC, Chikwamba R, Sparrow P, Fischer R, Mahoney R, Twyman RM (2005) Plant-derived pharmaceuticals-the road forward. Trends Plant Sci 10:580–585PubMedCrossRefPubMedCentralGoogle Scholar
  54. Maliga P (2004) Plastid transformation in higher plants. Annu Rev Plant Biol 55:289–313PubMedCrossRefPubMedCentralGoogle Scholar
  55. Mandal MK, Ahvari H, Schillberg S, Schiermeyer A (2016) Tackling unwanted proteolysis in plant production hosts used for molecular farming. Front Plant Sci 7:1–6CrossRefGoogle Scholar
  56. Mason HS, Warzecha H, Mor T, Arntzen CJ (2002) Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 8:324–329PubMedCrossRefPubMedCentralGoogle Scholar
  57. Mbewana S, Mortimer E, Pera FF, Hitzeroth II, Rybicki EP (2015) Production of H5N1 influenza virus matrix protein two ectodomain protein bodies in tobacco plants and in insect cells as a candidate universal influenza vaccine. Front Bioengg Biotechnol 3:197Google Scholar
  58. Merlin M, Pezzotti M, Avesani L (2017) Edible plants for oral delivery of biopharmaceuticals. Br J Clin Pharmacol 83:71–81PubMedCrossRefPubMedCentralGoogle Scholar
  59. Muynck B, de Navarre C, Nizet Y, Stadlmann J, Boutry M (2009) Different subcellular localization and glycosylation for a functional antibody expressed in Nicotiana tabacum plants and suspension cells. Transgenic Res 18:467–482PubMedCrossRefPubMedCentralGoogle Scholar
  60. Nahampun HN (2015) Plant molecular farming for the production of industrial enzymes and vaccines. Graduate theses and dissertations. 14962.
  61. Nerkar G, Thorat A, Sheelavantmath S, Kassa HB, Devarumath R (2018) Genetic transformation of sugarcane and field performance of transgenic sugarcane. In: Gosal S, Wani S (eds) Biotechnologies of crop improvement, vol 2. Springer, ChamCrossRefGoogle Scholar
  62. Oey M, Lohse M, Kreikemeyer B, Bock R (2009) Exhaustion of the chloroplast protein synthesis capacity by massive expression of a highly stable protein antibiotic. Plant J 57:436–445PubMedPubMedCentralCrossRefGoogle Scholar
  63. Ou J et al (2014) Transgenic rice endosperm as a bioreactor for molecular pharming. Plant Cell Rep 33:585–594PubMedCrossRefPubMedCentralGoogle Scholar
  64. Palaniswamy H, Syamaladevi DP, Mohan C, Philip A, Petchiyappan A, Narayanan S (2016) Vacuolar targeting of r-proteins in sugarcane leads to higher levels of purifiable commercially equivalent recombinant proteins in cane juice. Plant Biotechnol J 14:791–807PubMedCrossRefPubMedCentralGoogle Scholar
  65. Paul MJ, Teh AY, Twyman RM, Ma JK (2013) Target product selection-where can molecular pharming make the difference? Curr Pharm Des 19:5478–5485PubMedCrossRefPubMedCentralGoogle Scholar
  66. Pillay P, Schlüter U, van Wyk S, Kunert K, Vorster BJ (2014) Proteolysis of recombinant proteinsin bioengineered plant cells. Bioengineered 5:15–20PubMedCrossRefPubMedCentralGoogle Scholar
  67. Raven N, Rasche S, Kuehn C, Anderlei T, Klöckner W, Schuster F, Henquet M, Bosch D, Büchs J, Fischer R, Schillberg S (2015) Scaled-up manufacturing of recombinant antibodies produced by plant cells in a 200-L orbitally-shaken disposable bioreactor. Biotechnol Bioeng 112:308–321PubMedCrossRefPubMedCentralGoogle Scholar
  68. Rischer H, Häkkinen ST, Ritala A, Seppänen-Laakso T, Miralpeix B, Capell T, Christou P, Oksman-Caldentey KM (2013) Plant cells as pharmaceutical factories. Curr Pharm Des 19:5640–5660PubMedCrossRefPubMedCentralGoogle Scholar
  69. Schiermeyer A, Schinkel H, Apel S, Fischer R, Schillberg S (2005) Production of Desmodus rotundus salivary plasminogen activator a1(DSPAa1) into bacco is hampered by proteolysis. Biotechnol Bioeng 89:848–858PubMedCrossRefPubMedCentralGoogle Scholar
  70. Schillberg S, Twyman RM, Fischer R (2005) Opportunities for recombinant antigen and antibody expression in transgenic plants-technology assessment. Vaccine 23:1764–1769PubMedCrossRefPubMedCentralGoogle Scholar
  71. Shaaltiel Y, Bartfeld D, Hashmueli S et al (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 5:579–590PubMedCrossRefPubMedCentralGoogle Scholar
  72. Sirko A, Vanek T, Gora-Sochacka A, Redkiewicz P (2011) Recombinant cytokines from plants. Int J Mol Sci 12:3536–3552PubMedPubMedCentralCrossRefGoogle Scholar
  73. Spök A, Karner S (2008) Plant molecular farming- Opportunities and challenges. JRC Scientific and technical reports. In Stein A-J, Rodríguez-Cerezo E (eds) EUR-Scientific and Technical Research Series.
  74. Spök A, Twyman RM, Fischer R, Ma JKC, Sparrow PAC (2008) Evolution of a regulatory framework for plant-made pharmaceuticals. Trends Biotechnol 26:506–517PubMedCrossRefPubMedCentralGoogle Scholar
  75. Stoger E et al (2000) Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol 42:583–590PubMedCrossRefPubMedCentralGoogle Scholar
  76. Streatfield SJ, Lane JR, Brooks CA, Barker DK, Poage ML, Mayor JM et al (2003) Corn as a production system for human and animal vaccines. Vaccine 21:812–815PubMedCrossRefPubMedCentralGoogle Scholar
  77. Sun QY, Ding LW, Lomonossoff GP, Sun YB, Luo M, Li CQ et al (2011) Improved expression and purification of recombinant human serum albumin from transgenic tobacco suspension culture. J Biotechnol 155:164–172PubMedCrossRefPubMedCentralGoogle Scholar
  78. Tacket CO (2009) Plant-based oral vaccines: results of human trials. Curr Top MicrobiolImmunol 332:103–117Google Scholar
  79. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ (1998) Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 4:607–609PubMedCrossRefGoogle Scholar
  80. Tinazzi E, Merlin M, Bason C, Beri R, Zampieri R, Lico C, et al. (2015) Plant-derived chimeric virus particles for the diagnosis of primary Sjogren syndrome. Front Plant Sci 6:1080Google Scholar
  81. Tissot G, Canard H, Nadai M, Martone A, Botterman J, Dubald M (2008) Translocation of a protinin, a therapeutic protease inhibitor, into the thylakoid lumen of genetically engineered tobacco chloroplasts. Plant Biotechnol J 6:309–320PubMedCrossRefPubMedCentralGoogle Scholar
  82. Trivedi PK, Nath P (2004) MaExpl, an ethylene-induced expansin from ripening banana fruit. Plant Sci 167:1351–1358CrossRefGoogle Scholar
  83. Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R (2003) Molecular farming in plants: host systems and expression technology. Trends Biotechnol 21:570–578PubMedCrossRefPubMedCentralGoogle Scholar
  84. Twyman RM, Schillberg S, Fischer R (2013) Optimizing the yield of recombinant pharmaceutical proteins in plants. Curr Pharm Des 19:5486–5494PubMedCrossRefPubMedCentralGoogle Scholar
  85. Wilson SA, Roberts SC (2012) Recent advances towards development and commercialization of plant cell culture processes for the synthesis of biomolecules. Plant Biotechnol J 10:249–268PubMedCrossRefPubMedCentralGoogle Scholar
  86. Wirz H, Sauer-Budge AF, Briggs J, Sharpe A, Sudong S, Sharon A (2012) Automated production of plant-based vaccines and pharmaceuticals. J Lab Automat 17:449–457CrossRefGoogle Scholar
  87. Yano M, Hirai T, Kato K, Hiwasa-Tanase K, Fukuda N, Ezura H (2010) Tomato is a suitable material for producing recombinant miraculin protein in genetically stable manner. Plant Sci 178:469–473. CrossRefGoogle Scholar
  88. Yao J, Weng Y, Dickey A, Wang KY (2015) Plants as factories for human pharmaceuticals: applications and challenges. Int J Mol Sci 16:28549–28565PubMedPubMedCentralCrossRefGoogle Scholar
  89. Yoon S, Devaiah SP, Choi SE, Bray J, Love R, Lane J et al (2016) Overexpression of the cucumber expansin gene (Cs-EXPA1) in transgenic maize seed for cellulose deconstruction. Transgenic Res 25:173–186PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Gauri Nerkar
    • 1
  • G. S. Suresha
    • 1
  • Bakshi Ram
    • 1
  • C. Appunu
    • 1
  1. 1.Division of Crop ImprovementSugarcane Breeding InstituteCoimbatoreIndia

Personalised recommendations